Three News Items from Tripep

· Yet another active alphaHGA analogue has been identified · Patent for ChronVac-C® has been issued · A test model for Hepatitis C has been developed Today Tripep has acquired a patent related to the therapeutic vaccine ChronVac-C®. The patent covers the ChronVac-C® gene and its use in vaccines together with ribavirine. Furthermore, Tripep has acquired the commercial rights for a transgenic mouse model developed in collaboration with scientists at the Karolinska Institute. The mouse model, which is a spin off to the ChronVac-C® -project, can be used for the development of new drugs, as well as, therapeutic vaccines against hepatitis C. The liver of the mouse produces the ChronVac-C® gene product which corresponds to the Hepatitis C virus-enzyme protease. ”Our new patent validates the ChronVac-C® project. We are also happy to have acquired the animal model, which will be used in the further development of this project. In addition, Tripep will approach pharmaceutical companies for commercialisation of this unique animal model. This might well be the first product to be commercialised by Tripep. This, in it’s own right, would be an important step for Tripep” says Tripep’s CEO Jan Nilsson. Last year, Tripep announced the identification of two active analogues (chemical variants) of alphaHGA. The Company now can report on yet another active analogue to alphaHGA. ”This third alphaHGA analogue further strengthens our patent position regarding alphaHGA and shows that we are able to broaden the family of substances belonging to this entirely new class of anti HIV drugs” adds Tripep’s CEO Jan Nilsson. For more information, please contact: Jan Nilsson, CEO, Tripep AB Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@labmed.ki.se

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.